Meeder Asset Management Inc. lifted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 51,925.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,053 shares of the pharmaceutical company’s stock after purchasing an additional 27,001 shares during the quarter. Meeder Asset Management Inc.’s holdings in Vertex Pharmaceuticals were worth $14,144,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Vertex Pharmaceuticals during the 2nd quarter valued at approximately $11,975,849,000. State Street Corp raised its holdings in shares of Vertex Pharmaceuticals by 1.2% in the second quarter. State Street Corp now owns 11,871,459 shares of the pharmaceutical company’s stock worth $5,896,910,000 after buying an additional 141,320 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Vertex Pharmaceuticals by 1.1% during the second quarter. Wellington Management Group LLP now owns 3,247,658 shares of the pharmaceutical company’s stock worth $1,613,209,000 after buying an additional 35,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Vertex Pharmaceuticals by 1.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,086,683 shares of the pharmaceutical company’s stock worth $1,533,248,000 after buying an additional 29,287 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth $1,509,651,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Vertex Pharmaceuticals
In other news, Director Sangeeta Bhatia sold 271 shares of the firm’s stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $148,470.06. Following the sale, the director owned 4,653 shares of the company’s stock, valued at $2,549,192.58. This trade represents a 5.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Charles F. Wagner, Jr. sold 15,286 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $547.87, for a total transaction of $8,374,740.82. Following the transaction, the executive vice president directly owned 31,764 shares of the company’s stock, valued at approximately $17,402,542.68. This trade represents a 32.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 16,557 shares of company stock valued at $9,071,071. 0.20% of the stock is owned by company insiders.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the stock. Rothschild & Co Redburn boosted their price objective on shares of Vertex Pharmaceuticals from $570.00 to $580.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings downgraded Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, November 9th. Truist Financial increased their price objective on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Royal Bank Of Canada raised their price objective on Vertex Pharmaceuticals from $576.00 to $600.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 3rd. Finally, Wells Fargo & Company lifted their target price on Vertex Pharmaceuticals from $550.00 to $650.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $596.44.
Check Out Our Latest Stock Report on VRTX
Vertex Pharmaceuticals Stock Performance
Shares of VRTX stock opened at $536.46 on Thursday. The stock has a market cap of $136.01 billion, a PE ratio of 34.59, a price-to-earnings-growth ratio of 2.83 and a beta of 0.28. The business has a 50-day simple moving average of $522.61 and a 200-day simple moving average of $484.77. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. Vertex Pharmaceuticals Incorporated has a 52-week low of $412.27 and a 52-week high of $568.67.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The firm’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $4.80 EPS. On average, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current year.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
See Also
- Five stocks we like better than Vertex Pharmaceuticals
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
